Although several drugs have been used clinically to control T2D, such as biguanides [4], sulfonylureas [5], sodium-glucose co-transporter-2 (SGLT2) inhibitors [6], and thiazolidinediones [7], all of these drugs have some serious side-effects, especially resulting in gastrointestinal disorders [8,9] which affect both the drugs’ efficacy and the patient’s life. Here, SLC5A2 is linked to type 2 diabetes mellitus.